• Our Solution
    • Physicians
    • Patients
  • About Artrya
    • Who we are
    • Board of Directors
    • Careers
  • Investor Relations
    • Overview
    • ASX Announcements
    • Corporate Governance
    • Company Research
  • Contact Us
Request a demonstration

Updated Appendix 4C for Q4 FY22

Quarterly Activity Report and Appendix 4C for Q4 FY22

Quarterly Results Conference Call

Notification regarding unquoted securities – AYA

Notification regarding unquoted securities – AYA

Notification regarding unquoted securities – AYA

Change of Director’s Interest Notice – Bernie Ridgeway

Change of Director’s Interest Notice – Bernie Ridgeway

Artrya Appoints Accomplished American Physician as CMO

Conference Call – Update on US FDA Application

Previous 1 … 12 13 14 15 16 17 18 … 20 Next

Precise diagnosis. Personalized treatment.
Preventative care.

Choose Artrya as your trusted clinical partner.

Contact us today
Coronary artery disease.
We see you.

Sign up to our newsletter

Request a Demo
Contact Us

About Artrya
Investor Relations

Location
1257 Hay Street, West Perth, 6005
Follow us
X
LinkedIn

Salix Coronary Anatomy is listed on the Australian Register of Therapeutic Goods, ID 347719. Salix Central USA product (K243038) is cleared in the USA. For the availability of Salix in The EU, UK, or other jurisdictions, please contact us.

© 2025, Artrya. All rights reserved. Privacy Policy Terms and Conditions Indications for Use